{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:12:59Z","timestamp":1790280779357,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"New Faculty Start-up Grant Birla Institute of Technology and Science Pilani, Hyderabad Campus","award":["NFSG\/HYD\/2024\/H0946"],"award-info":[{"award-number":["NFSG\/HYD\/2024\/H0946"]}]},{"name":"New Faculty Start-up Grant Birla Institute of Technology and Science Pilani, Hyderabad Campus","award":["NFSG 05\/25\/1036"],"award-info":[{"award-number":["NFSG 05\/25\/1036"]}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPSG-2025-01-03159"],"award-info":[{"award-number":["IIRPSG-2025-01-03159"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12522-2","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:47:50Z","timestamp":1785826070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The NLRP3 inflammasome in chronic kidney disease progression: systematic review of preclinical models reveals a critical gap in pyroptosis research and therapeutic translation"],"prefix":"10.1007","volume":"53","author":[{"given":"Sagar A.","family":"More","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwal","family":"Dhokne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaykumar D.","family":"Nimbarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-445X","authenticated-orcid":false,"given":"Shrikant R.","family":"Mulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"12522_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113033","volume":"11","author":"S Altamura","year":"2023","unstructured":"Altamura S, Pietropaoli D, Lombardi F, Del Pinto R, Ferri C (2023) An overview of chronic kidney disease pathophysiology: the impact of gut dysbiosis and oral disease. Biomedicines 11:3033","journal-title":"Biomedicines"},{"key":"12522_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong AC et al (2024) Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 20:473\u2013485","journal-title":"Nat Rev Nephrol"},{"key":"12522_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1053\/j.akdh.2025.01.001","volume":"32","author":"N Kamath","year":"2025","unstructured":"Kamath N, Bjornstad E, Mashanga P, Obiagwu P, van Zwieten A, Pais P (2025) Inequities in pediatric nephrology: disparities in children\u2019s kidney health and access to care. Adv Kidney Dis Health 32:266\u2013278","journal-title":"Adv Kidney Dis Health"},{"key":"12522_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47100853","author":"Y Dong","year":"2025","unstructured":"Dong Y, Tong Y (2025) The pathogenesis of chronic kidney disease (CKD) and the preventive and therapeutic effects of natural products. Curr Issues Mol Biol. https:\/\/doi.org\/10.3390\/cimb47100853","journal-title":"Curr Issues Mol Biol"},{"key":"12522_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010263","author":"SF Rapa","year":"2019","unstructured":"Rapa SF, Di Iorio BR, Campiglia P, Heidland A, Marzocco S (2019) Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21010263","journal-title":"Int J Mol Sci"},{"key":"12522_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","volume":"7","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Tang B, Zhang C (2022) Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target Ther 7:182","journal-title":"Signal Transduct Target Ther"},{"key":"12522_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101427","author":"W-K Yu","year":"2025","unstructured":"Yu W-K, Zhu Q-R, Zhou L et al (2025) Small molecules targeting regulated cell death for chronic kidney disease therapy. J Pharm Anal. https:\/\/doi.org\/10.1016\/j.jpha.2025.101427","journal-title":"J Pharm Anal"},{"key":"12522_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41581-019-0158-z","volume":"15","author":"T Komada","year":"2019","unstructured":"Komada T, Muruve DA (2019) The role of inflammasomes in kidney disease. Nat Rev Nephrol 15:501\u2013520","journal-title":"Nat Rev Nephrol"},{"key":"12522_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2538798","volume":"47","author":"Y Sun","year":"2025","unstructured":"Sun Y, Pan G, Wang C, Xiao Z (2025) Mechanisms of NLRP3 inflammasome in chronic kidney disease and the effects of traditional Chinese medicines. Ren Fail 47:2538798","journal-title":"Ren Fail"},{"key":"12522_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116679","volume":"175","author":"W Ren","year":"2024","unstructured":"Ren W, Sun Y, Zhao L, Shi X (2024) NLRP3 inflammasome and its role in autoimmune diseases: a promising therapeutic target. Biomed Pharmacother 175:116679","journal-title":"Biomed Pharmacother"},{"key":"12522_CR11","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1152\/ajpcell.00416.2025","volume":"330","author":"SA More","year":"2026","unstructured":"More SA, Ghosh A, Kulkarni OP, Mulay SR (2026) Role of persistent necroinflammation in chronic tissue remodeling and organ fibrosis. Am J Physiol Cell Physiol 330:C40-c55","journal-title":"Am J Physiol Cell Physiol"},{"key":"12522_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","volume":"18","author":"S Paik","year":"2021","unstructured":"Paik S, Kim JK, Silwal P, Sasakawa C, Jo EK (2021) An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol 18:1141\u20131160","journal-title":"Cell Mol Immunol"},{"key":"12522_CR13","volume":"33","author":"G Huang","year":"2023","unstructured":"Huang G, Zhang Y, Zhang Y, Ma Y (2023) Chronic kidney disease and NLRP3 inflammasome: pathogenesis, development and targeted therapeutic strategies. Biochem Biophys Rep 33:101417","journal-title":"Biochem Biophys Rep"},{"key":"12522_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.kint.2019.01.014","volume":"96","author":"SR Mulay","year":"2019","unstructured":"Mulay SR (2019) Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases. Kidney Int 96:58\u201366","journal-title":"Kidney Int"},{"key":"12522_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/248563","volume":"2013","author":"A Mima","year":"2013","unstructured":"Mima A (2013) Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res 2013:248563","journal-title":"J Diabetes Res"},{"key":"12522_CR16","doi-asserted-by":"publisher","first-page":"5817348","DOI":"10.1155\/2020\/5817348","volume":"2020","author":"HY Su","year":"2020","unstructured":"Su HY, Yang C, Liang D, Liu HF (2020) Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury. Biomed Res Int 2020:5817348","journal-title":"Biomed Res Int"},{"key":"12522_CR17","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2025.13657","author":"X Jiao","year":"2025","unstructured":"Jiao X, Tian G (2025) Role of the NLRP3 inflammasome in diabetes and its complications (review). Mol Med Rep. https:\/\/doi.org\/10.3892\/mmr.2025.13657","journal-title":"Mol Med Rep"},{"key":"12522_CR18","doi-asserted-by":"publisher","first-page":"2193768","DOI":"10.1155\/2022\/2193768","volume":"2022","author":"W Zhao","year":"2022","unstructured":"Zhao W, Zhou L, Nov\u00e1k P et al (2022) Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: A Potential Target for Diabetic Nephropathy. J Diabetes Res 2022:2193768","journal-title":"J Diabetes Res"},{"key":"12522_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"12522_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW (2014) SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol 14:43","journal-title":"BMC Med Res Methodol"},{"key":"12522_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12:55\u201361","journal-title":"Res Synth Methods"},{"key":"12522_CR22","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2010020143","volume":"21","author":"A Vilaysane","year":"2010","unstructured":"Vilaysane A, Chun J, Seamone ME et al (2010) The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21:1732\u20131744","journal-title":"J Am Soc Nephrol"},{"key":"12522_CR23","doi-asserted-by":"publisher","first-page":"8316560","DOI":"10.1155\/2017\/8316560","volume":"2017","author":"H Guo","year":"2017","unstructured":"Guo H, Bi X, Zhou P, Zhu S, Ding W (2017) NLRP3 Deficiency Attenuates Renal Fibrosis and Ameliorates Mitochondrial Dysfunction in a Mouse Unilateral Ureteral Obstruction Model of Chronic Kidney Disease. Mediators Inflamm 2017:8316560","journal-title":"Mediators Inflamm"},{"key":"12522_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02563","volume":"9","author":"SM Kim","year":"2018","unstructured":"Kim SM, Kim YG, Kim DJ et al (2018) Inflammasome-independent role of NLRP3 mediates mitochondrial regulation in renal injury. Front Immunol 9:2563","journal-title":"Front Immunol"},{"key":"12522_CR25","doi-asserted-by":"publisher","first-page":"F1081","DOI":"10.1152\/ajprenal.00534.2015","volume":"310","author":"W Gong","year":"2016","unstructured":"Gong W, Mao S, Yu J et al (2016) NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5\/6 nephrectomy. Am J Physiol Renal Physiol 310:F1081-1088","journal-title":"Am J Physiol Renal Physiol"},{"key":"12522_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091252","author":"LC Li","year":"2021","unstructured":"Li LC, Chen WY, Chen JB et al (2021) The AST-120 recovers uremic toxin-induced cognitive deficit via NLRP3 inflammasome pathway in astrocytes and microglia. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines9091252","journal-title":"Biomedicines"},{"key":"12522_CR27","doi-asserted-by":"crossref","unstructured":"Song J, Navarro-Garcia JA, Wu J et al (2023) Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation. J Clin Invest 133","DOI":"10.1172\/JCI167517"},{"key":"12522_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1616542","volume":"16","author":"W Wen","year":"2025","unstructured":"Wen W, Tu B, Ren X et al (2025) Ultrasound combined with microbubble enhanced renoprotective effects of NLRP3 inflammasome inhibitor MCC950 in CKD model. Front Pharmacol 16:1616542","journal-title":"Front Pharmacol"},{"key":"12522_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03427-4","volume":"24","author":"MS Sabra","year":"2023","unstructured":"Sabra MS, Hemida FK, Allam EAH (2023) Adenine model of chronic renal failure in rats to determine whether MCC950, an NLRP3 inflammasome inhibitor, is a renopreventive. BMC Nephrol 24:377","journal-title":"BMC Nephrol"},{"key":"12522_CR30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.kint.2022.06.010","volume":"102","author":"K Shahzad","year":"2022","unstructured":"Shahzad K, Fatima S, Khawaja H et al (2022) Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. Kidney Int 102:766\u2013779","journal-title":"Kidney Int"},{"key":"12522_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154748","volume":"118","author":"M Wu","year":"2021","unstructured":"Wu M, Yang Z, Zhang C et al (2021) Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy. Metabolism 118:154748","journal-title":"Metabolism"},{"key":"12522_CR32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.kint.2017.09.022","volume":"93","author":"HJ Anders","year":"2018","unstructured":"Anders HJ, Suarez-Alvarez B, Grigorescu M et al (2018) The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int 93:656\u2013669","journal-title":"Kidney Int"},{"key":"12522_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.07.001","volume":"383","author":"S Li","year":"2019","unstructured":"Li S, Lin Q, Shao X et al (2019) NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation. Exp Cell Res 383:111488","journal-title":"Exp Cell Res"},{"key":"12522_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1159\/000485287","volume":"44","author":"W Ding","year":"2017","unstructured":"Ding W, Liu T, Bi X, Zhang Z (2017) Mitochondria-targeted antioxidant mito-tempo protects against aldosterone-induced renal injury in vivo. Cell Physiol Biochem 44:741\u2013750","journal-title":"Cell Physiol Biochem"},{"key":"12522_CR35","doi-asserted-by":"publisher","first-page":"17479","DOI":"10.18632\/oncotarget.8243","volume":"7","author":"W Ding","year":"2016","unstructured":"Ding W, Guo H, Xu C, Wang B, Zhang M, Ding F (2016) Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury. Oncotarget 7:17479\u201317491","journal-title":"Oncotarget"},{"key":"12522_CR36","doi-asserted-by":"publisher","first-page":"25101","DOI":"10.1074\/jbc.M114.578260","volume":"289","author":"Y Zhuang","year":"2014","unstructured":"Zhuang Y, Ding G, Zhao M et al (2014) NLRP3 inflammasome mediates albumin-induced renal tubular injury through impaired mitochondrial function. J Biol Chem 289:25101\u201325111","journal-title":"J Biol Chem"},{"key":"12522_CR37","doi-asserted-by":"publisher","first-page":"9404","DOI":"10.1002\/jcp.26784","volume":"233","author":"X Wu","year":"2018","unstructured":"Wu X, Chang SC, Jin J, Gu W, Li S (2018) NLRP3 inflammasome mediates chronic intermittent hypoxia-induced renal injury implication of the microRNA-155\/FOXO3a signaling pathway. J Cell Physiol 233:9404\u20139415","journal-title":"J Cell Physiol"},{"key":"12522_CR38","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/cvr\/cvy252","volume":"115","author":"SM Krishnan","year":"2019","unstructured":"Krishnan SM, Ling YH, Huuskes BM et al (2019) Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res 115:776\u2013787","journal-title":"Cardiovasc Res"},{"key":"12522_CR39","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/labinvest.3700445","volume":"86","author":"A Mima","year":"2006","unstructured":"Mima A, Matsubara T, Arai H et al (2006) Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Lab Invest 86:927\u2013939","journal-title":"Lab Invest"},{"key":"12522_CR40","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.2337\/db07-1726","volume":"57","author":"A Mima","year":"2008","unstructured":"Mima A, Arai H, Matsubara T et al (2008) Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy. Diabetes 57:1712\u20131722","journal-title":"Diabetes"},{"key":"12522_CR41","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/2211-5463.12400","volume":"8","author":"A Mima","year":"2018","unstructured":"Mima A, Yasuzawa T, King GL, Ueshima S (2018) Obesity-associated glomerular inflammation increases albuminuria without renal histological changes. FEBS Open Bio 8:664\u2013670","journal-title":"FEBS Open Bio"},{"key":"12522_CR42","doi-asserted-by":"publisher","first-page":"eabj3859","DOI":"10.1126\/sciimmunol.abj3859","volume":"6","author":"C Wang","year":"2021","unstructured":"Wang C, Yang T, Xiao J et al (2021) NLRP3 inflammasome activation triggers gasdermin D-independent inflammation. Sci Immunol 6:eabj3859","journal-title":"Sci Immunol"},{"key":"12522_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00467-013-2494-8","volume":"29","author":"HW Schnaper","year":"2014","unstructured":"Schnaper HW (2014) Remnant nephron physiology and the progression of chronic kidney disease. Pediatr Nephrol 29:193\u2013202","journal-title":"Pediatr Nephrol"},{"key":"12522_CR44","unstructured":"(2024) A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease."}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12522-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:47:53Z","timestamp":1785826073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12522-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12522"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12522-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest, financial or otherwise, are declared by the authors.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies involving human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1334"}}